Danaher Beats EPS but Lowers Revenue Outlook After Bioprocessing Miss

Shifts of roughly $100 million of revenue into next year caused Danaher to lower its FY2026 core revenue range, leaving investors cautious despite raised EPS guidance.

Overview

Danaher reported fiscal Q2 results on July 21, with $6.3 billion in revenue and adjusted EPS of $1.94, beating the $1.83 estimate.
Management said just over $100 million of revenue was pushed into next year because of customer project timing and trimmed the full‑year core revenue outlook to 3%–4% from a prior upper end of 6%.
The Life Sciences unit showed mid‑teens growth in bioprocessing orders, which signals demand, but reported bioprocessing revenue was weaker than expected and sensitive to project timing.
Investors reacted warily, sending the stock down about 11% after the report, prompting at least one major analyst to cut its price target and data showing hedge‑fund holdings and dollar exposure to Danaher fell quarter to quarter.
By contrast, Abbott posted clearer momentum in diagnostics and devices with a profit raise and stronger sales, a divergence that could shift investor preference within the health‑care group and increase scrutiny of Danaher’s execution.